What is ViewsML?
ViewsML is at the forefront of developing advanced AI solutions tailored for the healthcare sector, with a particular emphasis on cancer treatment, diagnosis, and research. The company's proprietary technology focuses on precision medicine and biomarker detection, enhancing clinical workflows by delivering rapid virtual diagnostics. This innovation significantly reduces the time and cost associated with traditional diagnostic methods. ViewsML's solutions are designed to benefit preclinical, translational, and clinical research, as well as contract research organizations, ultimately aiming to improve patient outcomes and accelerate project timelines through the application of deep learning for enhanced patient stratification and richer data sets across diverse biomarkers and therapeutic areas.
How much funding has ViewsML raised?
ViewsML has raised a total of $4.9M across 1 funding round:
Seed
$4.9M
Seed (2026): $4.9M with participation from Continuum Ventures, RiSC Capital, Wittington Ventures, Debiopharm, and Wutif
Key Investors in ViewsML
Continuum Ventures
Continuum Health Ventures is an early-stage venture capital fund focused on investing in Healthtech, TechBio, and Longevity startups that aim to transform healthcare from a sickcare model to a preventative approach. The firm provides strategic capital, operational support, and deep expertise to empower visionary founders.
RiSC Capital
RiSC Capital is a Canadian deep tech venture capital fund that specializes in investing in startups at the seed or pre-seed stage. With over 70 investments, they focus on supporting deep tech innovations and providing strategic guidance to their portfolio companies.
Wittington Ventures
Wittington Investments Limited is a private family Canadian company with a diverse portfolio including significant holdings in retail and property. While not exclusively a tech investor, their involvement suggests a strategic interest in innovative ventures.
What's next for ViewsML?
With the recent influx of major strategic investment, ViewsML is poised to accelerate its expansion and further refine its AI-driven precision medicine platform. The substantial capital infusion, totaling $4.9M, suggests a company entering a critical scaling phase, likely focusing on market penetration, further research and development, and potentially expanding its team of AI and oncology specialists. This strategic backing from investors like Continuum Ventures and RiSC Capital, who specialize in healthtech and deep tech respectively, indicates confidence in ViewsML's technological innovation and its potential to disrupt cancer care pathways. The company is expected to leverage this financing to solidify its position as a leader in AI-powered diagnostics and research, driving advancements in patient stratification and biomarker detection.
See full ViewsML company page
